National Institutes of Health: Myeloproliferative Disorders trials

The registry lists 40 Myeloproliferative Disorders studies with National Institutes of Health as lead sponsor. 4 are open to participants now and 9 have results posted.

Phase 1 22Phase 2 20No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)RecruitingNCT06661915Phase 2
• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingNCT06303193Phase 1/2
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingNCT05554406Phase 2
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• Preventing Stem Cell Transplant Complications With a Blood Separator MachineCompletedNCT01866839Phase 1/2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersTerminatedNCT00074490Phase 2Results posted
• Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
• The National Myelodysplastic Syndromes (MDS) StudyCompletedNCT02775383
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
• Molecular Changes and Biomarkers in Chronic Myeloproliferative DisordersCompletedNCT00433862
• Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
• Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
• Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
• Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
• 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 2
• Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersCompletedNCT00114257Phase 1
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Peripheral Stem Cell Transplant in Treating Patients With High-Risk LeukemiaTerminatedNCT00066417Phase 2
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1